TL;DR
FDA-approved marijuana drugs and state-medical-licensed products moved from Schedule I to Schedule III of the Controlled Substances Act.
Recreational marijuana is still federally illegal. Hemp under 0.3% THC is unchanged.
April 28, 2026.
Required by U.S. obligations under the 1961 Single Convention on Narcotic Drugs after HHS recommended Schedule III based on accepted medical use.
Q&A
No. The rule only applies to FDA-approved drug products containing marijuana, and to marijuana covered by state-issued medical licenses. Adult-use recreational marijuana is still federally illegal. State recreational markets remain in the same gray zone they were before.
Schedule I means no accepted medical use — heroin, LSD. Schedule III means moderate-to-low abuse potential and accepted medical use — like Tylenol with codeine, ketamine, or anabolic steroids. Moving marijuana from I to III is a major legal recognition that it has medical value.
If you hold a state-issued license to manufacture, distribute, or dispense marijuana for medical purposes, the rule covers you. You will need a DEA registration through a new expedited fast-track process under 21 CFR Part 1301. Major upside: likely exit from Section 280E tax restrictions.
Likely yes for state-licensed medical operators covered by the rule. Section 280E denies business deductions for trafficking in Schedule I or II substances. Schedule III is not in 280E, so covered businesses should regain normal deductions. Talk to a CPA — IRS guidance is still developing.
No change from this rule. FDA-approved CBD drugs were moved to Schedule V in 2018. Hemp under 0.3 percent delta-9 THC remains federally legal under the 2018 Farm Bill. Note: starting November 12, 2026, the hemp definition shifts to total THC under 0.3 percent (Public Law 119-37) — a separate change.
This is the open question. Federal banking law treats Schedule III differently than Schedule I, and many bank policies were tied specifically to Schedule I status. Most banking lawyers expect new policy guidance from FinCEN and bank regulators in coming months.
Only for FDA-approved marijuana drug products. Plain marijuana flower from a dispensary is not an FDA-approved drug — it is covered separately under the state medical marijuana licensing piece of the rule.
A future DEA could try to reschedule again, but it would face the same Single Convention treaty obligation that drove this rule. Moving marijuana back to Schedule I would likely require congressional action or treaty changes.
No. The rule does not legalize personal cultivation. Federal law still prohibits home cultivation outside of state-licensed medical programs that explicitly authorize patient cultivation. Check your state's specific medical-marijuana rules.
This rule covers marijuana only. Psilocybin remains in Schedule I under federal law. State-level psilocybin programs (Oregon, Colorado) remain in the same federal gray zone.
Federal manufacturing and distribution licenses are available only through DEA registration tied to state medical marijuana licenses (using the new expedited 21 CFR Part 1301 process). There is still no federal license for adult-use or unrestricted cultivation — it must be through a state medical program.
Probably not immediately. Most workplace drug testing policies are governed by employer choice or specific federal agency rules (like DOT). Schedule III status alone does not change those policies. Watch for new federal guidance on safety-sensitive jobs.